These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 10656436)
1. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. De Santis S; Pace A; Bove L; Cognetti F; Properzi F; Fiore M; Triaca V; Savarese A; Simone MD; Jandolo B; Manzione L; Aloe L Clin Cancer Res; 2000 Jan; 6(1):90-5. PubMed ID: 10656436 [TBL] [Abstract][Full Text] [Related]
2. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat. Cavaletti G; Petruccioli MG; Marmiroli P; Rigolio R; Galbiati S; Zoia C; Ferrarese C; Tagliabue E; Dolci C; Bayssas M; Griffon Etienne G; Tredici G Anticancer Res; 2002; 22(6C):4199-204. PubMed ID: 12553056 [TBL] [Abstract][Full Text] [Related]
3. Outcome of peroneal neuropathies in patients with systemic malignant disease. Rubin DI; Kimmel DW; Cascino TL Cancer; 1998 Oct; 83(8):1602-6. PubMed ID: 9781954 [TBL] [Abstract][Full Text] [Related]
4. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Argyriou AA; Chroni E; Koutras A; Ellul J; Papapetropoulos S; Katsoulas G; Iconomou G; Kalofonos HP Neurology; 2005 Jan; 64(1):26-31. PubMed ID: 15642899 [TBL] [Abstract][Full Text] [Related]
5. Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Pisano C; Pratesi G; Laccabue D; Zunino F; Lo Giudice P; Bellucci A; Pacifici L; Camerini B; Vesci L; Castorina M; Cicuzza S; Tredici G; Marmiroli P; Nicolini G; Galbiati S; Calvani M; Carminati P; Cavaletti G Clin Cancer Res; 2003 Nov; 9(15):5756-67. PubMed ID: 14654561 [TBL] [Abstract][Full Text] [Related]
6. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer]. Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639 [TBL] [Abstract][Full Text] [Related]
7. A pilot study on the relation between cisplatin neuropathy and vitamin E. Bove L; Picardo M; Maresca V; Jandolo B; Pace A J Exp Clin Cancer Res; 2001 Jun; 20(2):277-80. PubMed ID: 11484987 [TBL] [Abstract][Full Text] [Related]
8. Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis. Aloe L; Manni L; Properzi F; De Santis S; Fiore M Auton Neurosci; 2000 Dec; 86(1-2):84-93. PubMed ID: 11269929 [TBL] [Abstract][Full Text] [Related]
9. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity. Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499 [TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Krishnan AV; Goldstein D; Friedlander M; Kiernan MC Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395 [TBL] [Abstract][Full Text] [Related]
11. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study. Almadrones L; McGuire DB; Walczak JR; Florio CM; Tian C Oncol Nurs Forum; 2004 May; 31(3):615-23. PubMed ID: 15146227 [TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-carboplatin chemotherapy does not cause encephalopathy in patients with ovarian cancer: a prospective EEG mapping study in 28 patients. Mayerhofer K; Bodner K; Saletu B; Bodner-Adler B; Anderer P; Hefler L; Schindl M; Kaider A; Leodolter S; Kainz C Anticancer Res; 2001; 21(1B):803-8. PubMed ID: 11299847 [TBL] [Abstract][Full Text] [Related]
16. The electrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1 diabetes mellitus. Karsidag S; Morali S; Sargin M; Salman S; Karsidag K; Us O Diabetes Res Clin Pract; 2005 Mar; 67(3):211-9. PubMed ID: 15713353 [TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Davis ID; Kiers L; MacGregor L; Quinn M; Arezzo J; Green M; Rosenthal M; Chia M; Michael M; Bartley P; Harrison L; Daly M Clin Cancer Res; 2005 Mar; 11(5):1890-8. PubMed ID: 15756015 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Weitz IC; Israel VK; Waisman JR; Presant CA; Rochanda L; Liebman HA Thromb Haemost; 2002 Aug; 88(2):213-20. PubMed ID: 12195692 [TBL] [Abstract][Full Text] [Related]
19. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. Cavaletti G; Frigeni B; Lanzani F; Piatti M; Rota S; Briani C; Zara G; Plasmati R; Pastorelli F; Caraceni A; Pace A; Manicone M; Lissoni A; Colombo N; Bianchi G; Zanna C; J Peripher Nerv Syst; 2007 Sep; 12(3):210-5. PubMed ID: 17868248 [TBL] [Abstract][Full Text] [Related]